Package 72626-2601-1

{"route": ["ORAL"], "spl_id": "bd8387fe-8338-4241-b084-aec76726f8a9", "openfda": {"nui": ["N0000191256", "N0000185503", "N0000190113", "N0000191493", "N0000191258"], "unii": ["013TE6E4WV", "WJ6CA3ZU8B"], "rxcui": ["1591943"], "spl_set_id": ["46f4a73b-0cd6-4902-9092-3ac79e882c1a"], "pharm_class_epc": ["Hepatitis C Virus NS5A Inhibitor [EPC]", "Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]"], "pharm_class_moa": ["P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "RNA Replicase Inhibitors [MoA]"], "manufacturer_name": ["Asegua Therapeutics LLC"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "2 BLISTER PACK in 1 CARTON (72626-2601-1)  / 14 TABLET, FILM COATED in 1 BLISTER PACK", "package_ndc": "72626-2601-1", "marketing_start_date": "20190101"}], "brand_name": "Ledipasvir and Sofosbuvir", "product_id": "72626-2601_bd8387fe-8338-4241-b084-aec76726f8a9", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Breast Cancer Resistance Protein Inhibitors [MoA]", "Hepatitis C Virus NS5A Inhibitor [EPC]", "Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]", "P-Glycoprotein Inhibitors [MoA]", "RNA Replicase Inhibitors [MoA]"], "product_ndc": "72626-2601", "generic_name": "Ledipasvir and Sofosbuvir", "labeler_name": "Asegua Therapeutics LLC", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Ledipasvir and Sofosbuvir", "active_ingredients": [{"name": "LEDIPASVIR", "strength": "90 mg/1"}, {"name": "SOFOSBUVIR", "strength": "400 mg/1"}], "application_number": "NDA205834", "marketing_category": "NDA AUTHORIZED GENERIC", "marketing_start_date": "20190101", "listing_expiration_date": "20261231"}